FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. In oppose to the moving average for the last 50 days, trading by +22.25% upper at the present time.Wells Fargo, on the other hand, stated in their research note that they expect to see EDIT stock at the price of $28. Editas Medicine, Inc. (NASDAQ:EDIT) went up by 1.45% from its latest closing price when compared to the 1-year high value of $36.78 and move down -25.36%, while EDIT stocks collected -11.60% of loss with the last five trading sessions. Equity return holds the value -63.20%, with -33.40% for asset returns.After a stumble in the market that brought EDIT to its low price for the period of the last 52 weeks, Editas Medicine, Inc. was unable to take a rebound, for now settling with -20.23% of loss for the given period.EDIT stocks went down by -11.60% for the week, with the monthly jump of 8.39% and a quarterly performance of 44.89%, while its annual performance rate touched 18.59%. The predicted price for EDIT socks in the upcoming period according to SunTrust is $45 based on the research report published on June 18, 2020.Editas Medicine, Inc. (NASDAQ: EDIT) The 36 Months beta value for EDIT stocks is at 2.03, while of the analysts out of 0 who provided ratings for Editas Medicine, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. In addition, Editas Medicine, Inc. saw -0.91% in overturn over the period of a single year with a tendency to cut further losses.The current profitability levels are settled at -686.39 for the present operating margin. Editas Medicine, Inc () Stock Market info Recommendations: Buy or sell Editas Medicine stock? NASDAQ Updated Jul 24, 2020 11:55 PM Editas Medicine Inc. EDIT 30.50 0.17 (0.59%). It was founded in 2013 with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures and licensed CRISPR patents from the Broad Institute's Feng Zhang, patents from Harvard's David Liu and George Church … Editas Medicine (NASDAQ: EDIT) was one of them. Albright Charles, the Chief Scientific Officer of Editas Medicine, Inc., sold 622 shares at the value of $26.95 during a trade that took place back on Feb 07, which means that Albright Charles is holding 31,524 shares at the value of $16,763 based on the most recent closing price.Evercore ISI gave “Outperform” rating to EDIT stocks, setting the target price at $28 in the report published on April 12, 2019.Many brokerage firms have already submitted their reports for EDIT stocks, with SunTrust repeating the rating for EDIT shares by setting it to “Buy”. The receivables turnover for Editas Medicine, Inc. is 91.66 with the total asset turnover at the value of 0.04. Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Editas Medicine has granted the underwriter a 30-day option to purchase up to an additional 900,000 shares of common stock on the same terms and conditions. The offering is expected to close on or about June 26, 2020, subject to customary closing conditions.